AstraZeneca reports promising Seroquel SR data from schizophrenia studies
Anglo-Swedish drug major AstraZeneca says that data from trials of a sustained-release formulation of Seroquel (quetiapine fumarate), indicate that a once-daily administration of the drug significantly improves the symptoms associated with schizophrenia. In addition, the results showed that treatment, when given as part of a three-step dosing program designed to reach an effective dose on the second day, increased the time to psychiatric relapse.
Examined in acute and stable schophrenics
The results, which were announced during AstraZeneca's presentation at the European Congress of Psychiatry in the Spanish capital Madrid, are derived from two clinical studies that examined the drug's impact upon the disease at various stages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze